'Study drug' diaporamas de présentation

971 views • 58 slides

Did that just happen? And What do I do now?

Did that just happen? And What do I do now?. Identifying and Reporting Adverse Events and Protocol Deviations. Elizabeth Mathis, CCRP 18 February 2014. Adverse Events Serious Adverse Events Protocol Deviations. Overview and Objectives. http://www.hhs.gov/ohrp/policy/advevntguid.html.

585 views • 43 slides

The Bangkok Tenofovir Study

Bangkok Metropolitan Administration. Thailand Ministry of Public Health. The Bangkok Tenofovir Study. An HIV pre-exposure prophylaxis trial in Thailand: participant adherence and study results .

658 views • 41 slides

How to Evaluate a Randomized Clinical Trial ( RCT ): What Every Pharmacist Should Know

How to Evaluate a Randomized Clinical Trial ( RCT ): What Every Pharmacist Should Know . Pharmacists often need to review primary literature to make patient specific recommendation or apply information to clinical practice.

645 views • 40 slides

2011 US Diabetes Statistics

2011 US Diabetes Statistics. Diabetes affects 25.8 million people in the US (8.3% of the U.S. population) 18.8 million diagnosed, 7.0 million undiagnosed 10.9 million (26.9%) of those aged ?65 have diabetes 215,000 people <20

454 views • 38 slides

462 views • 31 slides

Definitions, Scaling & Graphs

416 views • 30 slides

Lilliam Rosario, Ph.D. Director Office of Computational Science

427 views • 29 slides

Christopher S. Brazel, Ph.D., P.E.

Christopher S. Brazel, Ph.D., P.E. . Associate Professor: University of Alabama Department of Chemical and Biological Engineering. The University of Alabama College of Engineering Department of Chemical and Biological Engineering.

479 views • 28 slides

Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Rot

Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled Study. Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Roth,

448 views • 25 slides

Adverse Event Reporting

821 views • 22 slides

Bashi Ratterree, RN, BSN, CCRP

Bashi Ratterree, RN, BSN, CCRP Nurse Coordinator, CHM OHSU Knight Cancer Institute Mail code: UHN73C 503-494-9982 ratterre@ohsu.edu. A Phase II Trial of the Safety and Efficacy of Abc-001 for the Treatment of CoordinatorStressitis. Adverse Events Reporting Exercise. 2 yr trial

379 views • 21 slides

Overview of Investigational Drug Services and Study Drug Accountability

Overview of Investigational Drug Services and Study Drug Accountability. Merrell Lim, Pharm.D. Investigational Drug Services Pharmacist mlim1@clarian.org 317-944-1900. Learning Objectives. Learn about services provided by investigational drug services (IDS) pharmacy

720 views • 20 slides

Efficacy Results from Three Pivotal Efficacy Trials

Efficacy Results from Three Pivotal Efficacy Trials. Karl F. Mann, M.D. Professor and Chairman Director, Department of Addictive Behavior and Addiction Medicine Central Institute of Mental Health of Mannheim University of Heidelberg. Pivotal European Efficacy Studies - Objective.

450 views • 19 slides

Statistical Review

Statistical Review. Dr. Shan Sun-Mitchell. ENT 00-02 Primary endpoint: Time to treatment failure by day 50. Placebo BDP Patients randomized 67 62 Number of treatment failures 30(45%) 18 (29%)

261 views • 15 slides

Funding: The TRACER trial was funded by Merck & Co., Inc.

224 views • 14 slides

Renee Stapleton 7/07/05

Developing a Phase II RCT: The effects of n-3 fatty acids on lung and systemic inflammation in patients with acute lung injury. Renee Stapleton 7/07/05. Outline. Choosing a research question and selecting study design Process of designing the trial Timeline Budget Lessons learned.

214 views • 14 slides

Randomization & Consent Scenarios

Randomization & Consent Scenarios. Deneil Harney MPH, MSW HSP Coordinator University of Michigan. Randomization Scenarios.

231 views • 12 slides

CAB Draft Discussion Tuesday, January 14, 2014 CWRU/UH CRS CAB Meeting

A5336 A Phase IIa , Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults. CAB Draft Discussion Tuesday, January 14, 2014 CWRU/UH CRS CAB Meeting. Inflammation.

297 views • 6 slides

BMT CTN 0302 Randomized Phase II Trial of Four Acute GVHD Therapies

HCT (BM, PBSC, CB). Acute GVHD (diagnosed in past 48 hours). Yes, requiring systemic therapy. No. RANDOMIZATION. Prednisone, and Etanercept , or MMF*, or Ontak, or Pentostatin . If progressive GVHD within 7 days, or no response within 14 days, treat

340 views • 1 slides